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SUPPLEMENTARY NOTES
ABSTRACT
We had previously identified androgen responsive genes in LNCaP prostate cancer cells using microarray technology. I have performed a high throughput loss of function screen using RNA interference (RNAi) in order to identify androgen responsive genes that are critical for androgen induced proliferation. I am currently validating the candidate genes identified in my screen, and investigating whether they function in prostate tumor progression. When completed, my studies will lead to the identification and characterization of androgen regulated genes involved in prostate cancer.
SUBJECT TERMS
Prostate cancer, RNAi, functional genomics, androgen signaling Abstract: We had previously identified androgen responsive genes in LNCaP prostate cancer cells using microarray technology. I have performed a high throughput loss of function screen using RNA interference (RNAi) in order to identify androgen responsive genes that are critical for androgen induced proliferation. I am currently validating the candidate genes identified in this screen and investigating whether these genes contribute to prostate tumor progression. When completed, my studies will lead to the identification and characterization of androgen regulated genes involved in prostate cancer.
Subject Terms: Prostate cancer, RNAi, functional genomics, androgen signaling
Introduction:
Prostate cells depend on a crucial level of androgenic stimulation for proliferation and survival. Although hormone therapy is the mainstream treatment for prostate cancer, the targets of androgen receptor signaling crucial for prostate cell growth have not been elucidated. The identification of androgen responsive genes and pathways that are critical for proliferation will shed light into the mechanism of androgen action, and yield insight into how cancer cells subvert regulation of controlled proliferation and become refractory to hormone manipulation. Using microarray technology, we had previously identified 58 androgen responsive genes in LNCaP human prostate cancer cells. In this project, I have conducted a loss of function screen to identify androgen responsive genes that are critical of androgen induced proliferation.
Body:
Task 1: Perform a loss of function screen to identify genes critical for androgen receptor stimulated cell proliferation
Over the past year, I have optimized the conditions for and conducted a high throughput RNA interference screen in LNCaP cells to ablate the expression of androgen regulated genes. 300 short hairpin RNAs were used in the screen and were delivered into cells by lentiviral infection. PSA production and proliferation were monitored to identify androgen target genes critical for proliferation (Figure 1 ). I am currently validating the set of genes that have scored in both the PSA production and the proliferation assays. The ability of each of these shRNAs to suppress their target genes is also being investigated to ensure correlation with functional phenotype (Figure 2 ).
Task 2:
Study the relevance of the validated genes in tumor progression and its possible role in the development of androgen independent prostate cancer With the validation phase for Task 1 being near complete, I have begun to conduct preliminary experiments to undertake Task 2. I have overexpressed the genes identified in Task 1 in immortalized and transformed prostate epithelial cells that my lab had previously generated (1) . I have also overexpressed the genes in androgen dependent LNCaP and LAPC4 cells. I am conducting in vitro proliferation and soft agar assays to determine whether the genes that were identified in this screen play a role in prostate cancer progression. For example, c-Maf scored in the screen, and I have assessed the consequences of suppressing c-Maf in the androgen dependent cell line LNCaP (Figure 3 and data not shown). Additionally, I am assaying for the proliferation of the cells in androgen depleted medium to determine whether the genes function in androgen independence. I will soon be initiating in vivo xenograft experiments to corroborate the in vitro data.
Key Research and Training Accomplishments:
1-
Optimized conditions for conducting a high throughput screen in LNCaP cells.
2-
Conducted an RNAi screen in LNCaP cells. 3-Acquired significant expertise in manipulating high throughput genomic tools.
Reportable Outcomes:
Once the aforementioned studies are completed, I will write a manuscript describing the results for publication.
